SUBSCRIBE
SUBSCRIBE
News   Drug Development

Cell>Point Completes Phase 2 of Cancer Diagnostic Phase 2/3 Trial

June 28, 2010 | 
1 min read

CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer (NSCLC).

Clinical research Phase II
MORE ON THIS TOPIC
Pictured: Entrance to Pfizer's office in Belgium
Breast cancer
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Dollar banknote cut into pieces on a yellow background
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
2D illustration showing scientists' hands editing a DNA strand
Gene editing
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern collage with human heart and hands stock illustration
Cardiovascular disease
Deep Dive: Cardiovascular Disease Back in the Spotlight
March 10, 2025
 · 
2 min read
 · 
Heather McKenzie